| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/30/2001 | WO2001002568A3 Human genes and gene expression products |
| 08/30/2001 | WO2001002540A3 Adenoviral vectors for treating disease |
| 08/30/2001 | WO2000077250A3 Method for circularizing oligonucleotides around a double stranded nucleic acid, resulting structures and uses thereof |
| 08/30/2001 | WO2000074701A3 Method and composition for inhibiting cardiovascular cell proliferation |
| 08/30/2001 | WO2000041719A9 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
| 08/30/2001 | WO2000040733A9 Human cyclic nucleotide pdes |
| 08/30/2001 | WO2000040614A9 Characterization of the soc/crac calcium channel protein family |
| 08/30/2001 | WO2000040597A9 Method and composition for angiogenesis inhibition |
| 08/30/2001 | US20010018598 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
| 08/30/2001 | US20010018511 Anticancer agent |
| 08/30/2001 | US20010018509 Growth differeniation factor-3 |
| 08/30/2001 | US20010018508 Tumour necrosis factor binding ligands |
| 08/30/2001 | US20010018507 Complexing |
| 08/30/2001 | US20010018427 Anticholesterol agent |
| 08/30/2001 | US20010018423 Anticoagulant agents |
| 08/30/2001 | US20010018422 Anticancer agents |
| 08/30/2001 | US20010018421 Polypeptides |
| 08/30/2001 | US20010018420 Method for alleviating pain or providing an analgesic effect in a patient |
| 08/30/2001 | US20010018419 Isolated and purified; Rh antigens which can be immobilized and used in hematology, for isolation and purification of anti-Rh antibodies from solutions; useful in treatment of hemolytic disease of newborn |
| 08/30/2001 | US20010018418 Method of promoting angiogenesis |
| 08/30/2001 | US20010018417 Of sodium lauryl sulfate, a buffering agent to provide acidic pH when the mixture is added to water, and colloidal silica; mixture added to animal feeds |
| 08/30/2001 | US20010018416 Treating hepatitis-C, aberrant apoptosis or AIDS with composition of N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP) of high purity |
| 08/30/2001 | US20010018415 Treating cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretion by administering Botulinum toxin type A |
| 08/30/2001 | US20010018414 Modified vitamin K-dependent polypeptides |
| 08/30/2001 | US20010018212 Molecular weight of 14,000 to 24,000 daltons; treating infectious diseases and malignant tumors with said protein |
| 08/30/2001 | US20010018204 Administering composition of tissure factor pathway inhibitor, homolog or active fragment with anti-proliferative activity; treating angiogenesis related diseases; cancer; arthritis; macular degeneration; diabetic retinopathy |
| 08/30/2001 | US20010018198 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same |
| 08/30/2001 | US20010018190 Predicting sensitivity of prostate cancer |
| 08/30/2001 | US20010018189 Crohn's disease, skin disorders, antiallergens |
| 08/30/2001 | US20010018060 Use of particular fatty substances which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter |
| 08/30/2001 | US20010018059 Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
| 08/30/2001 | US20010018058 Isolated polypeptide comprising an immunogenic portion of a breast protein comprising an amino acid sequence encoded by a polynucleotide |
| 08/30/2001 | US20010018051 Inhibition of allograft and concordant xenograft rejection |
| 08/30/2001 | US20010018050 Administering protein C; avoiding bleeding, toxicity and side effects of anticoagulant agents |
| 08/30/2001 | US20010018048 Novel adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors |
| 08/30/2001 | CA2683009A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2418496A1 Secretory polypeptides and corresponding polynucleotides |
| 08/30/2001 | CA2416250A1 Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders |
| 08/30/2001 | CA2401868A1 Molecules for diagnostics and therapeutics |
| 08/30/2001 | CA2401647A1 Inter-alpha-trypsin as a marker for sepsis |
| 08/30/2001 | CA2401219A1 Vertebrate globin |
| 08/30/2001 | CA2401195A1 Pai-2 conjugates for the treatment and imaging of cancer |
| 08/30/2001 | CA2401113A1 Transporters and ion channels |
| 08/30/2001 | CA2401096A1 Methods and compositions for inhibiting angiogenesis |
| 08/30/2001 | CA2401076A1 Molecules for disease detection and treatment |
| 08/30/2001 | CA2401070A1 Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| 08/30/2001 | CA2401031A1 Tlp peptides and dna sequences coding the same |
| 08/30/2001 | CA2400948A1 Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
| 08/30/2001 | CA2400876A1 Novel protein and gene encoding the protein |
| 08/30/2001 | CA2400874A1 Membrane estrogen receptor-directed therapy in breast cancer |
| 08/30/2001 | CA2400863A1 Staphylococcal gtpase obg nucleotide sequence encoding staphylococcal gtp-binding protein |
| 08/30/2001 | CA2400842A1 Novel compounds |
| 08/30/2001 | CA2400838A1 Novel method for down-regulation of amyloid |
| 08/30/2001 | CA2400823A1 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity |
| 08/30/2001 | CA2400610A1 Endoparasiticidal compositions comprising a cyclic depsipeptide |
| 08/30/2001 | CA2400606A1 New phosphodiesterase type 7b |
| 08/30/2001 | CA2400544A1 Method of modulating glycosylation pathways |
| 08/30/2001 | CA2400215A1 Hla binding peptides and their uses |
| 08/30/2001 | CA2400099A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | CA2400040A1 Integrin antagonists |
| 08/30/2001 | CA2399999A1 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 08/30/2001 | CA2399298A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2399255A1 Caspase activated prodrugs therapy |
| 08/30/2001 | CA2399020A1 Process of purification of hcg and recombinant hcg purified by that method |
| 08/30/2001 | CA2398275A1 Human polynucleotides, polypeptides, and antibodies |
| 08/30/2001 | CA2397813A1 Method and reagent for the inhibition of grid |
| 08/30/2001 | CA2397705A1 Compounds related to or derived from gfr.alpha.4 and their use |
| 08/30/2001 | CA2394088A1 Method for transdermal or intradermal delivery of molecules |
| 08/30/2001 | CA2368364A1 A stable composition comprising epidermal growth factor as an active ingredient |
| 08/29/2001 | EP1127944A1 Method for screening compound inhibiting signal transduction of inflammatory cytokine |
| 08/29/2001 | EP1127894A1 Method of diagnosis of transmissible spongiform encephalopathy (TSE) |
| 08/29/2001 | EP1127893A2 Compositions and methods for the treatment and diagnosis of breast cancer |
| 08/29/2001 | EP1127884A1 Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them |
| 08/29/2001 | EP1127883A2 Oxamides as IMPDH inhibitors |
| 08/29/2001 | EP1127869A1 Novel compounds and medicinal use thereof |
| 08/29/2001 | EP1127581A1 Malleable paste for filling bone defects |
| 08/29/2001 | EP1127579A2 Method for increasing bioavailability of oral pharmaceutical compositions |
| 08/29/2001 | EP1127578A1 Remedies for bone metabolic errors |
| 08/29/2001 | EP1127577A2 Ligand for the c-kit receptor and methods of use thereof |
| 08/29/2001 | EP1127576A1 Uses of NM23-polypeptides in skin and intestinal disorders |
| 08/29/2001 | EP1127170A1 Human pan-hcv human monoclonal antibodies |
| 08/29/2001 | EP1127168A2 Method for determining the susceptibility to developing sepsis and therapeutics for the treatment of sepsis |
| 08/29/2001 | EP1127151A2 Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors |
| 08/29/2001 | EP1127136A1 Delivery of superoxide dismutase to neuronal cells |
| 08/29/2001 | EP1127134A1 Rotavirus subunit vaccine |
| 08/29/2001 | EP1127133A2 Polypeptide mediating cell permeability |
| 08/29/2001 | EP1127132A1 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| 08/29/2001 | EP1127131A2 Connective tissue growth factor (ctgf) and methods of use |
| 08/29/2001 | EP1127129A1 Myosin heavy chain homolog |
| 08/29/2001 | EP1127127A1 Regulator of notch signaling activity |
| 08/29/2001 | EP1127126A1 G-protein coupled receptors, homologous to ebv-induced gpcr 2 (ebi-2). methods to seek for ligands thereof |
| 08/29/2001 | EP1127123A2 Cell surface glycoproteins |
| 08/29/2001 | EP1127122A2 Growth factor related molecules |
| 08/29/2001 | EP1127119A1 Compounds and methods for modulating claudin-mediated functions |
| 08/29/2001 | EP1127117A1 Opg fusion protein compositions and methods |
| 08/29/2001 | EP1127115A1 Antisense oligomer |
| 08/29/2001 | EP1127113A2 Transgenic and cloned mammals |
| 08/29/2001 | EP1127111A2 Coenzyme a-utilizing enzymes |
| 08/29/2001 | EP1127110A1 Modified exosomes and uses |
| 08/29/2001 | EP1127109A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |